Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$2.91
▼ $0.14 (-4.6%)
Market data updated: 09/25 09:20 AM
Fundamentals updated: 09/25/2026
News analyzed: 09/25/2026
Market Cap
$140.26M
Day Range
$2.90 - $3.06
52-Week Range
$2.56 - $7.32
Beta
—
Next Earnings
16.11.2026
Support
$2.90
Resistance
$4.63
LFMD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-54.0% (1Y)
Strengths: 12/31 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 25.3%
Growth
Biggest negative driver
Operating margin
Operating margin: -4.5% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
10d ago · $3.44
Evidence: FOMO score jumped from 6 to 40 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
63
Value
55
Momentum
19
Risk
40
Sentiment
44
Fundamental
63
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of LifeMD, Inc. has centered on its financial performance and market valuation amid broader industry scrutiny. The company faced downward revisions in analyst price targets and fair value estimates due to weaker-than-expected guidance, alongside a 48% share price decline over the past year. Its Q2 2026 earnings call highlighted ongoing challenges, while external reports flagged FDA concerns over compounded GLP-1 drugs—including those tied to LifeMD’s business—raising regulatory and market uncertainty. Analysts maintained a "Buy" rating but lowered targets, reflecting cautious optimism.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about LifeMD, Inc.. News trend score: 44. Reason: 6 of the last 20 articles are negative, versus 5 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
16
🎯 Conviction (vs. Emotion)
42
Psychology
93
Fundamentals
63
Technical
19
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-30%
Market Narrative
28
Fundamental Reality
42
Narrative Gap
-14
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for LFMD strongly suggests loss aversion as traders appear reluctant to accept further declines after a 37% drop over three months. The muted volume (0.98x average) and proximity to support (2.6% above) reinforce caution, while weak momentum (-9.4% ROC) and negative sentiment (20/100) align with defensive positioning. Anchoring (score 48) may also play a role, as traders hold near support levels. The key open question is whether the stock can sustain a rebound or if the narrative gap (-25) signals lingering skepticism about fundamentals. The absence of FOMO or euphoria further indicates a risk-averse stance.
Updated: 09/09/2026, 12:48 AM
What could change this?
👥 What the crowd believes
"HC Wainwright & Co. analyst Yi Chen maintains LifeMD with a Buy but lowers the price target from $10 to $9"
"LifeMD trades at a historically low 0.75x TTM revenue multiple amid a 48% one-year share price decline"
"analysts lower targets on weaker guidance"
"FDA says it has received 990 adverse event reports tied to compounded semaglutide"
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 31/100
🗣️ Why do they disagree?
Based on the high scores from Mackay (97), Lynch (96), Marks‑cycle (95) and Schwager (86), the model estimates that these investors would see LFMD as a growth‑oriented, disciplined setup with little crowd mania and a favorable risk‑reward profile. In contrast, Graham’s defensive (36) and enterprising (30) scores, along with the efficient‑market view (33), signal that value‑focused frameworks find the stock insufficiently cheap or margin‑protected. The lower marks from Loeb (21), Bagehot (20) and Housel (0) further highlight concerns about capital risk, liquidity and volatility that would deter more risk‑averse or market‑neutral approaches. Consequently, the debate reflects a split between methodologies that prioritize growth and cycle positioning versus those that emphasize intrinsic safety, valuation cushions and market efficiency.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 96
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 81
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 72
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 71
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 52
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 51
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 50
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 32
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 283 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 10 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
85.7%
Operating Margin
-4.5%
Net Margin
7.4%
EBITDA Margin
—
ROE
62.0%
ROA
20.4%
ROIC
—
EPS
$0.25
Cash
$36.79M
Total Debt
—
Current Ratio
1.25
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$2.91
Estimated Fair Value (DCF)
$3.16
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+8.7%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
18.3%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 18.3% | $7.58M | $6.96M |
| 2 | 14.4% | $8.67M | $7.30M |
| 3 | 10.4% | $9.58M | $7.40M |
| 4 | 6.5% | $10.20M | $7.22M |
| 5 | 2.5% | $10.45M | $6.79M |
Base FCF (last actual year)
$6.41M
Terminal Value
$164.80M
Present Value of Terminal Value
$107.11M
Enterprise Value
$142.78M
Net Debt
$0
Equity Value
$142.78M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.50
Tangible Book Value per Share (Tangible NAV)
$0.26
Sentiment based on basic keywords (not AI) — 5 positive, 9 neutral, 6 negative out of the last 20 articles.
Yahoo · 22.9.2026
Yahoo · 20.9.2026
Yahoo · 19.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 15.9.2026
Benzinga · 1.9.2026
Simply Wall St. · 23.8.2026
SeekingAlpha · 20.8.2026
Motley Fool · 13.8.2026
SeekingAlpha · 11.8.2026
Benzinga · 7.8.2026
MT Newswires · 6.8.2026
Moby · 6.8.2026
Benzinga · 6.8.2026
SeekingAlpha · 6.8.2026
MarketBeat · 6.8.2026
Benzinga · 6.8.2026
LifeMD, Inc. (LFMD) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
LFMD currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, LFMD's estimated fair value is $3.16, which is 8.7% above the current price of $2.91. This is one valuation model among several signals in the fair-value category, not a price target.
LFMD's technical score is 19/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 25.3%; Earnings per share (EPS) growth: 141.7%; Net income growth: 167.0%.
Based on the real signals StockIQ computed: Operating margin: -4.5% (negative); ATR: 6.5% of price; Calmar: -0.19 (3y annualized return -15.6% / max drawdown 82.5%).
StockIQ has no recorded dividend payment history for LFMD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Strawn John R Jr | Grant/Award from Employer | 11.8.2026 | 498,001 | +35,000 | — |
| LAROVERE JOAN | Grant/Award from Employer | 11.8.2026 | 142,050 | +35,000 | — |
| MACRAE CALUM ARCHIBALD | Grant/Award from Employer | 11.8.2026 | 35,000 | +35,000 | — |
| Simon Roberto | Grant/Award from Employer | 11.8.2026 | 35,000 | +35,000 | — |
| LAROVERE JOAN | Grant/Award from Employer | 11.8.2026 | 35,000 | +35,000 | — |
| Strawn John R Jr | Grant/Award from Employer | 11.8.2026 | 35,000 | +35,000 | — |
| DiTrolio Joseph | Grant/Award from Employer | 11.8.2026 | 35,000 | +35,000 | — |
| DiTrolio Joseph | Grant/Award from Employer | 11.8.2026 | 308,413 | +35,000 | — |
| MACRAE CALUM ARCHIBALD | Grant/Award from Employer | 11.8.2026 | 73,865 | +35,000 | — |
| Simon Roberto | Grant/Award from Employer | 11.8.2026 | 288,175 | +35,000 | — |
| Sripad Umesh | Grant/Award from Employer | 1.6.2026 | 75,000 | +75,000 | — |
| Sripad Umesh | Grant/Award from Employer | 1.6.2026 | 75,000 | +75,000 | — |
| Kavthekar Atul | Grant/Award from Employer | 11.5.2026 | 337,500 | +337,500 | — |
| Kavthekar Atul | Grant/Award from Employer | 11.5.2026 | 337,500 | +337,500 | — |
| Strawn John R Jr | Grant/Award from Employer | 4.5.2026 | 463,001 | +50,000 | — |
| Strawn John R Jr | Grant/Award from Employer | 4.5.2026 | 50,000 | +50,000 | — |
| Simon Roberto | Grant/Award from Employer | 4.5.2026 | 50,000 | +50,000 | — |
| Simon Roberto | Grant/Award from Employer | 4.5.2026 | 253,175 | +50,000 | — |
| Pisano Christopher A | Grant/Award from Employer | 30.3.2026 | 200,000 | +200,000 | — |
| Pisano Christopher A | Grant/Award from Employer | 30.3.2026 | 200,000 | +200,000 | — |
| FRIEDEMAN JESSICA | Open Market Sale | 9.12.2025 | 15,000 | -15,000 | $3.61 |
| FRIEDEMAN JESSICA | Open Market Sale | 9.12.2025 | 205,000 | -15,000 | $3.61 |
| LAROVERE JOAN | Grant/Award from Employer | 6.10.2025 | 22,365 | +22,365 | — |
| Strawn John R Jr | Grant/Award from Employer | 6.10.2025 | 22,365 | +22,365 | — |
| Strawn John R Jr | Grant/Award from Employer | 6.10.2025 | 413,001 | +22,365 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
7,395,023 shares short as of 2026-09-15 · vs. 7,239,178 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
69.4% of trading volume this week was short selling, vs. 66.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology